Herpes zoster vaccine: What are the potential benefits for the ageing and older adults?

European Geriatric Medicine

Volumn 2, Issue 3, 2011, Pages 134-139

  Lang, P O ^a   Michel, J P ^a  

^a UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

Author keywords

Burden of illness; Herpes zoster; Herpes zoster vaccine; Post herpetic neuralgia

Indexed keywords

ACICLOVIR; ANALGESIC AGENT; ANTIVIRUS AGENT; CORTICOSTEROID; FAMCICLOVIR; PENCICLOVIR; PLACEBO; PREDNISONE; VALACICLOVIR; VARICELLA ZOSTER VACCINE;

AGING; ARTICLE; COST EFFECTIVENESS ANALYSIS; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; HEALTH CARE COST; HERPES ZOSTER; HUMAN; IMMUNIZATION; IMMUNOGENICITY; INCIDENCE; META ANALYSIS; PAIN; POSTHERPETIC NEURALGIA; PREVENTION STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; RASH; SYSTEMATIC REVIEW; TREATMENT CONTRAINDICATION; UNSPECIFIED SIDE EFFECT;

EID: 79960906295     PISSN: 18787649     EISSN: 18787657     Source Type: Journal    
DOI: 10.1016/j.eurger.2011.06.001     Document Type: Article

References (59)

1. M.D. Brisson, and W.J. Edmunds Epidemiology of varicella-zoster in England and Wales J Med Virol 70 Suppl. 1 2003 S9 S14
2. W.J. Edmunds, M. Brisson, and J.D. Rose The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales Vaccine 19 2001 3076 3090 (Pubitemid 32324035)
3. R.P. Insinga, R.F. Itzler, J.M. Pellissier, P. Saddier, and A.A. Nikas The incidence of herpes zoster in a United States administrative database J Gen Intern Med 20 2005 748 753 (Pubitemid 41141008)
4. W. Opstelten, J.W. Mauritz, N.J. de Wit, A.J. van Wijck, W.A. Stalman, and G.A. van Essen Herpes zoster and post-herpetic neuralgia: incidence and risk indicators using in general practice research database Fam Pract 19 2002 471 475 (Pubitemid 35244231)
5. C. Chidiac, J. Buxelles, J.P. Daures, T. Hoang-Xuan, P. Morel, and A. Leplege Characteristics of patients with herpes zoster on presentation to practitioners in France Clin Infect Dis 33 2001 62 69 (Pubitemid 32554504)
6. R.E. Hope-Simpson Postherpetic neuralgia J R Coll Gen Pract 25 1975 571 575
7. S.L. Thomas, and A.J. Hall What does epidemiology tell us about risk factors for herpes zoster? Lancet Infect Dis 4 2004 26 33 (Pubitemid 38057055)
8. D.W. Wareham, and J. Breuer Herpes zoster BMJ 334 2007 1211 1215 (Pubitemid 46954586)
9. F.T. Scott, R.W. Johnson, M. Leedham-Green, E. Davies, W.J. Edmunds, and J. Breuer The burden of herpes zoster: a prospective population based study Vaccine 24 2006 1308 1314 (Pubitemid 43222038)
10. A.N. Stein, H. Britt, C. Harrison, E.L. Conway, A. Cunningham, and C.R. MacIntyre Herpes zoster burden of illness and health care resource utilisation in the Australian population aged 50 years and older Vaccine 27 2009 520 529
11. P.O. Lang, F. Herrmann, and J.P. Michel Varicella-zoster vaccine N Eng J Med 357 2007 89
12. M.D. Brisson, K.E. Schmader, M.J. Levin, R. Johnson, M.N. Oxman, and D. Patrick The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study CMAJ 182 2010 1731 1736
13. P.O. Lang Herpes zoster: the associated burden and its prevention Geriatr Psychol Neuropsychiatr Vieil 9 2011 [In press]
14. M.J. Wood, R. Kay, R.H. Dworkin, S.J. Soong, and R.J. Whitley Oral acyclovir therapy accelerates pain resolution in patients with herpes zoster: a meta-analysis of placebo-controlled trials Clin Infect Dis 22 1996 341 347 (Pubitemid 26056166)
15. J.L. Jackson, R. Gibbons, G. Meyer, and L. Inouye The effect of treating herpes zoster with oral acyclovir in preventing postherpetic neuralgia. A meta-analysis Arch Intern Med 157 1997 909 912 (Pubitemid 28337042)
16. K.R. Beutner, D.J. Friedman, C. Forszpaniak, P.L. Andersen, and M.J. Wood Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults Antimicrob Agents Chemother 39 1995 1546 1553
17. S. Tyring, R.A. Barbarash, J.E. Nahlik, A. Cunningham, J. Marley, and M. Heng Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia. A randomized, double-blind, placebo-controlled trial. Collaborative famciclovir herpes zoster study group Ann Intern Med 123 1995 89 96
18. M.J. Wood Current experience with antiviral therapy for acute herpes zoster Ann Neurol 35 1994 S65 S68
19. Q. Li, N. Chen, J. Yang, M. Zhou, D. Zhou, and Q. Zhang Antiviral treatment for preventing postherpetic neuralgia Cochrane Database Syst Rev 15 2 2009 [CD006866]
20. P.O. Lang, M. Zarate-Lagunes, and S. Pautex Herpes zoster and post-herpetic neuralgia in old adults Rev Med Suisse 4 2008 2398 2404
21. P.O. Lang, J. Belmin, and J.P. Michel Herpes zoster in old adults Press Med 38 2009 571 583
22. P.O. Lang, S. Pautex, J. Belmin, and J.P. Michel Herpes zoster-related pain in aged individuals: How to manage it safely Eur Geriatr Med 1 2010 273 278
23. T. McGuire, K.B. Wells, M.L. Bruce, J. Miranda, R. Scheffer, and M. Durham Burden of illness Ment Health Serv Res 4 2002 179 185 (Pubitemid 36032780)
24. P.M. Coplan, K.E. Schmader, A. Nikas, I.S. Chan, P. Choo, and M.J. Levin Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: adaptation of the brief pain inventory J Pain 5 2004 344 356 (Pubitemid 39164674)
25. R.W. Johnson, and R.H. Dworkin Treatment of herpes zoster and postherpetic neuralgia BMJ 326 2003 748 750 (Pubitemid 36408042)
26. R.H. Dworkin, R.W. Johnson, J. Breuer, J.W. Gnann, M.J. Levin, and M. Backonja Recommendations for the management of herpes zoster Clin Infect Dis 44 2007 S1 S26
27. J.W. Gnann, and R.J. Whitley Herpes Zoster N Eng J Med 347 2002 340 346 (Pubitemid 34815357)
28. R.W. Johnson, Wasner, P. Saddier, and R. Baron Herpes zoster and postherpetic neuralgia: optimizing management in the elderly patient Drugs Aging 25 2008 991 1006
29. R.J. Whitley, H. Weiss, J.W. Gnann Jr., S. Tyring, G.J. Mertz, and P.G. Pappas Acyclovir with and without prednisone for the treatment of herpes zoster. A randomized, placebo-controlled trial Ann Intern Med 125 1996 376 383 (Pubitemid 126449707)
30. M.J. Wood, R.W. Johnson, M.W. McKendrick, J. Taylor, B.K. Mandal, and J. Crooks A randomized trial of acyclovir for 7 days or 21 days with and without prednisolone for treatment of acute herpes zoster N Engl J Med 330 1994 896 900 (Pubitemid 24094969)
31. V. Esmann, J.P. Geil, S. Kroon, H. Fogh, N.A. Peterslund, and C.S. Petersen Prednisolone does not prevent post-herpetic neuralgia Lancet 2 1987 126 129 (Pubitemid 17092174)
32. D. Benoldi, S. Mirizzi, A. Zucchi, and F. Allegra Prevention of post-herpetic neuralgia. Evaluation of treatment with oral prednisone, oral acyclovir, and radiotherapy Int J Dermatol 30 1991 288 290
33. D.W. Kimberlin, and R.J. Whitley Varicella-zoster vaccine for the prevention of herpes zoster N Eng J Med 356 2007 1338 1343 (Pubitemid 46513299)
34. M.J. Levin, and A.R. Hayward The varicella vaccine. Prevention of herpes zoster Infect Dis Clin North Am 10 1996 657 675 (Pubitemid 26285293)
35. P.O. Lang Adverse effects of the herd immunity or when childhood vaccination becomes deleterious for the epidemiology of infectious diseases in adults Geriatr Psychol Neuropsychiatr Vieil 9 2011 11 19
36. European Medicines Agency. Zostavax: summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/ zostavax/H-674-PI-en-pdf. [accessed May 26, 2011].
37. Merck. Varivax: prescribing information [online]. Available from URL: http://www.merck.com/product/usa/pi-circulars/v/varivax-pi.pdf. [accessed May 26, 2011].
38. M.N. Oxman, M.J. Levin, and G.R. Johnson A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults N Eng J Med 352 2005 2271 2284
39. o G-409 plus poster] 48th annual meeting of the interscience conference on antimicrobial agents and chemiotherapy/46th annual meeting of the infectious diseases society of America Oct 6-8; Washington, DC 2008
40. K.E. Schmader, G.R. Johnson, P. Saddier, M. Ciarleglio, W.W.B. Wang, and J.H. Zhang Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults J Am Geriatr Soc 58 2010 1634 1641
41. R. Fried Zoster vaccine in older adults J Am Geriatr Soc 58 2010 1799 1800
42. U.S. Food and Drug Administration, 2006. Approval Letter-Zostavax [online]. Available from URL: http://www.fda.gov/BiologicsBloodVaccines/ Vaccines/Approved Products/ucm132873.htm.[accessed December 22, 2010].
43. M. Sanford, and G.M. Keating Zoster vaccine (Zostavax). A review of its use in preventing herpes zoster and postherpetic neuralgia in older adults Drugs Aging 27 2010 159 176
44. M.S. Simberkoff, R.D. Arbeit, and G.R. Johnson Safety of herpes zoster vaccine in the Shingles prevention study Ann Intern Med 1532 2010 545 554
45. J. Hornberger, and K. Robertus Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults Ann Intern Med 145 2006 317 325 (Pubitemid 46768588)
46. Centers for disease control prevention (CDC). Prevention of herpes zoster recommendations of the advisory committee on immunization practices (ACIP) MMWR 57 2008 1 30
47. A.J. van Hoek, N. Gay, A. Melegaro, W. Opstelten, and W.J. Edmunds Estimating the cost-effectiveness of vaccination against herpes zoster in England and Wales Vaccine 27 2009 1454 1467
48. J.M. Pellissier, M. Brisson, and M.J. Levin Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults Vaccine 25 2007 8326 8337 (Pubitemid 350087379)
49. M.B. Rothberg, A. Virapongse, and K.J. Smith Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults Clin Infect Dis 44 2007 1280 1288 (Pubitemid 46717289)
50. M. Brisson, J.M. Pellissier, S. Camden, C. Quach, and P. De Wals The potential cost-effectiveness of vaccination against herpes zoster and post-herpetic neuralgia Hum Vaccin 4 2008 238 245
51. M. Najafzadeh, C.A. Marra, E. Galanis, and D.M. Patrick Cost effectiveness of herpes zoster vaccine in Canada Pharmacoeconomics 27 2009 991 1004
52. T.A. Lieu, I. Ortega-Sanchez, G.T. Ray, D. Rusinak, W.K. Yih, and P.W. Choo Community and patient values for preventing herpes zoster Pharmacoeconomics 26 2008 235 249 (Pubitemid 351278369)
53. T.A. Lieu, G.T. Ray, I. Ortega-Sanchez, K. Kleinman, D. Rusinak, and L.A. Prosser Willingness to pay for a QALY based on community member and patient preferences for temporary health states associated with herpes zoster Pharmacoeconomics 27 2009 1005 1016
54. F.A. Komara Herpes zoster vaccination: benefits and barriers J Am Osteopath Assoc 109 6 suppl. 2 2009 S22 S24
55. L.P. Hurley, M.C. Lindley, R. Harpaz, S. Stokley, M.F. Daley, and L.A. Crane Barriers to the use of herpes zoster vaccine Ann Intern Med 152 2010 555 560
56. J.P. Michel, M. Gusmano, P.R. Blank, and I. Philp Vaccination and healthy ageing: How to make life-course vaccination a successful public health strategy Eur Geriatr Med 1 2010 155 165
57. L.I. Gilderman, J.F. Lawless, T.M. Nolen, T. Sterling, R.Z. Rutledge, and D.A. Fernsler A double-blind, randomized, controlled, multicenter safety and immunogenicity study of a refrigerator-stable formulation of Zostavax Clin Vaccine Immunol 15 2008 314 319 (Pubitemid 352025537)
58. P. Lu, G.L. Euler, A.O. Jumaan, and Harpaz R Herpes zoster vaccination among adults aged 60 years or older in the United States 2007: uptake of the first new vaccine to target seniors Vaccine 27 2009 882 888
59. Centers for disease control prevention (CDC). Adult immunization programs in non-traditional settings: quality standards and guidance for program evaluation - a report of the National vaccine advisory committee MMWR 49 2000 [RR-1]